Chronic Villitis of unknown etiology (VUE): Obstetrical features, outcome and treatment.


Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
11 2021
Historique:
received: 19 04 2021
revised: 15 09 2021
accepted: 21 10 2021
pubmed: 29 10 2021
medline: 29 3 2022
entrez: 28 10 2021
Statut: ppublish

Résumé

Villitis of unknown etiology (VUE) is characterized by lympho-histiocytic infiltrates, which are predominant within the villous stroma. VUE can be of low grade i.e. affecting less than 10 contiguous villi or high grade with either patchy or diffuse subgroups (the later concerning more than 30 % of distal villi). Several other placental lesions could be associated with VUE, in particular in diffuse subgroups, such as diffuse perivillous fibrin deposition and chronic intervillositis. One of the most characteristic features of VUE is the late onset of fetal growth restriction after 32 weeks of gestation, and earlier detection of villitis should first raise an infectious origin. High grade VUE has been associated with fetal growth restriction, prematurity, fetal deaths, recurrent pregnancy loss, central nervous system injury and is characterized by relatively high risk of recurrence (25-50 %). Prospective and well-designed studies are necessary to determine the real prevalence of these adverse pregnancy events associated with VUE. Data about the management of VUE are extremely scarce and thus no recommendation based on the literature review could be actually done.

Identifiants

pubmed: 34710823
pii: S0165-0378(21)00168-6
doi: 10.1016/j.jri.2021.103438
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103438

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Arsène Mekinian (A)

Sorbonne Université, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne (DMU i3), F-75012, Paris, France. Electronic address: arsene.mekinian@aphp.fr.

Kamila Kolanska (K)

AP-HP, Hôpital Tenon, service d'Obstétrique et de Procréation Médicalement Assistée, Université Paris 06, UMRS-938, F-75020, Paris, France.

Meryam Cheloufi (M)

AP-HP, Hôpital Trousseau, service d'Obstétrique, F-75012, Paris, France.

Aurore Coulomb (A)

Sorbonne Université, AP-HP, Hôpital Trousseau, service d'anatomopathologie, F-75012, Paris, France.

Jonathan Cohen (J)

Clinique Saint Thérèse, service d'Obstétrique, F-75017, Paris, France.

Noémie Abisror (N)

Sorbonne Université, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne (DMU i3), F-75012, Paris, France.

Marie Bornes (M)

AP-HP, Hôpital Tenon, service d'Obstétrique et de Procréation Médicalement Assistée, Université Paris 06, UMRS-938, F-75020, Paris, France.

Gilles Kayem (G)

AP-HP, Hôpital Trousseau, service d'Obstétrique, F-75012, Paris, France.

Jaume Alijotas-Reig (J)

Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebrón University Hospital, and Departament of Medicine Universitat Autonoma de Barcelona, Barcelona, Spain.

Olivier Fain (O)

Sorbonne Université, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne (DMU i3), F-75012, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH